Psilocybin
Fraser Johnston Inspires Healthy and Cooperative Communities – Podcast Episode #33
On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Fraser Johnston of Entheotech and PsyDelve. After graduating from…
On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Fraser Johnston of Entheotech and PsyDelve.
After graduating from the University of Edinburgh BSc, Fraser emigrated to Canada and began scaling digital education and e-commerce platforms globally. He then became the Program Lead at one of the top tech incubators in Canada, Accelerate Okanagan (AO).
During his time at AO he helped hundreds of businesses scale through innovative program design, strategic planning and detailed operational reviews. A pioneer in the biotech industry, Fraser was inspired by his own personal healing journey to amass the world’s largest catalog of psilocybin mushroom strains to bring these powerful natural medicines to the world. His vision to inspire healthy and cooperative communities is behind everything EntheoTech does.
Season Four is Coming Soon
Stay tuned for more great conversations… weekly.
If you just found out about the podcast, we encourage you to check out the Psychedelic Invest Podcast page or subscribe to the show on your favorite audio platform to binge and catch up.
The Transcription is Coming Soon
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin5 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment